Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying zelicapavir, a new oral medication that stops the replication of Respiratory Syncytial Virus RSV. This Phase 2 trial is evaluating zelicapavir as a potential treatment for RSV infection in children aged 28 days to 36 months who have symptoms of RSV. The study compares zelicapavir to a placebo to assess its effects and safety in both hospitalized and non-hospitalized children. Participants are randomly assigned to receive either zelicapavir oral suspension or a matching placebo once daily for 7 days. The study monitors the time it takes for RSV symptoms to completely resolve, along with other outcomes such as the severity of symptoms, viral load changes, and any hospitalizations during the study period. These assessments occur mainly from Day 1 through Day 14, with safety followed until Day 35. During the trial, caregivers and children will be assessed regularly to track symptom resolution and viral levels using specific measurement tools. Safety is carefully monitored by recording any adverse events up to Day 35. The study spans from the initial dosing period through follow-up visits, ensuring comprehensive evaluation of zelicapavirs potential in treating RSV in young children.
Actively Recruiting
Researchers are studying the daily use of Rifapentine combined with Isoniazid to prevent tuberculosis in children under 13 years old, including those with and without HIV. This Phase III trial aims to find the appropriate dose of this combination taken once daily for 28 days. The study will include up to 144 children divided into two groups based on HIV status and will take place at multiple locations. Participants will receive the study drugs by oral dispersible tablets, grouped by weight into five categories. Children with HIV will also be assessed for their use of Dolutegravir as part of their antiretroviral therapy. The treatment period lasts 28 days, followed by a 24-week follow-up to monitor safety, tolerability, and drug levels in the blood. Both groups will be closely observed to assess how the drugs are processed in their bodies and any adverse effects. During the study, participants will have blood tests to measure drug concentrations and monitor liver, kidney, and blood cell function. Parent or guardian reports on treatment acceptability and adherence will be collected. Researchers will track adverse events throughout the treatment and follow-up periods. The total participation duration includes the initial 28-day dosing phase and subsequent 24 weeks of monitoring to ensure safety and effectiveness of the regimen.
Actively Recruiting
Researchers are studying acute febrile illness in patients older than 28 days who live in rural areas of Laos, Myanmar, Thailand including the Thai-Myanmar border region, and Bangladesh. This observational study aims to describe the causes, clinical outcomes, and host biomarkers associated with these illnesses, which last 14 days or less. The study is part of a larger community-based network seeking to improve understanding and future interventions for febrile illness in low- and middle-income countries in South and Southeast Asia. The study involves two main parts Work Package A collects data from village health workers and local health facilities to understand the incidence and outcomes of febrile illness at the community level. Work Package B recruits patients seeking care at higher-level health facilities who may be more severely ill. In Work Package B, researchers collect various samples including venous blood and respiratory specimens for detailed diagnostic testing such as blood cultures, serological assays, molecular diagnostics, and host biomarker assays. Participants will be monitored for about one month to measure the prevalence of pathogens and recovery status. The study will analyze the association between host biomarkers and clinical outcomes to help create electronic decision-support tools for village health workers. These tools and other interventions will be tested later to improve assessment, triage, and treatment of patients with febrile illness. The total duration of participation and follow-up is approximately one month.
Actively Recruiting
Atrial fibrillation AF is a major cause of heart-related illness and death, especially among Asian patients who face higher risks of serious bleeding such as brain hemorrhage compared to non-Asians. This research, called the COhort of antithrOmbotic use and cLinical outcomes in patients with Atrial Fibrillation COOL-AF Phase 2, aims to study how antithrombotic medication use changes over time and how these changes affect health outcomes in people with AF. The study is observational and conducted across multiple centers in Thailand. Participants in this study have known or newly diagnosed non-valvular AF and are followed without any intervention or treatment assigned by the study. The study plans to enroll about 3680 patients over two years from 33 centers. Participants will be monitored every 6 months for up to 3 years to observe patterns of medication use, particularly warfarin and non-vitamin K antagonist oral anticoagulants NOACs, and clinical events including stroke, systemic embolism, bleeding, heart attacks, and heart failure. Throughout the study, patients will have regular check-ins every six months to track their medication usage and health status. Researchers will collect data on important outcomes such as rates of stroke, bleeding events, and quality of life. The studys primary focus is on long-term safety and effectiveness of antithrombotic treatments in this population. The total participation duration can be up to 3 years, ensuring thorough observation of clinical outcomes and treatment patterns.
Actively Recruiting
Researchers are evaluating doravirine as an alternative to dolutegravir in people newly diagnosed with HIV-1 infection who have not yet received treatment. This Phase III, open-label, randomized clinical trial aims to determine if doravirine combined with tenofovir and lamivudine is not less effective than dolutegravir combined with tenofovir and lamivudine or emtricitabine. The study will be conducted across multiple countries including Brazil, Cameroon, Cte dIvoire, France, Mozambique, and Thailand, enrolling 610 participants. Participants will be randomly assigned to one of two groups one receiving doravirine 100 mg plus tenofovir DF 300 mg and lamivudine 300 mg daily, and the other receiving dolutegravir 50 mg plus tenofovir DF 300 mg and either lamivudine or emtricitabine daily. The treatment period will last for 96 weeks after starting antiretroviral therapy ART, with primary assessment at week 48 to measure viral suppression. During the study, participants will undergo evaluations to monitor viral load, drug resistance, metabolic health, body weight changes, liver and kidney function, cardiovascular status, and mental health. Adherence to ART will be tracked, and blood samples will be taken to measure drug levels and immune cell counts. The research team will review virological efficacy and safety outcomes at weeks 48 and 96, supporting a comprehensive understanding of the treatments effects over nearly two years of participation.
Actively Recruiting
Researchers are evaluating the effects of tozorakimab, a drug given by injection under the skin, in adults with uncontrolled asthma who are already using medium to high doses of inhaled corticosteroids. This phase IIb study is designed to find the right dose and assess how safe and effective tozorakimab is for reducing severe asthma attacks over a period of 26 to 52 weeks. Participants will be randomly assigned to receive one of two doses of tozorakimab or a placebo, all given subcutaneously. The study is double-blind, meaning neither participants nor researchers know who receives which treatment. The treatment period lasts up to 52 weeks with regular monitoring. The study will measure asthma exacerbation rates, lung function changes, asthma control, quality of life, and drug levels in the blood. During the trial, participants will complete daily asthma diaries to track symptoms and medication use, and attend visits for lung function tests, questionnaires, and blood samples. Safety and antibody responses to the drug will be monitored throughout. Participation lasts up to about one year, including screening and treatment, with regular visits to assess health and response to the study drug.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the epidemiological impact and cost-effectiveness of long-acting antiretrovirals for HIV prevention among Thai men who have sex with men MSM and transgender women TGW. The study includes discrete choice experiments DCEs to understand preferences for different pre-exposure prophylaxis PrEP options, as well as analysis of routine service data. The findings will guide mathematical modeling of long-acting PrEP uptake and its impact on HIV prevention. The study has three phases. Phase I involves in-depth interviews IDIs and focus group discussions FGDs with current, previous, or interested PrEP users to identify important attributes for PrEP choices. Phase II pilots the DCEs with convenience samples to refine the survey. Phase III launches two final surveys for MSM and TGW, collecting data on demographics, risk behavior, HIV and STI testing, PrEP knowledge, use, and preferences across attributes like product form, dosing frequency, provider type, and cost. Participants will take part in interviews, group discussions, and surveys conducted either in person or online. Data collected includes sociodemographic information, risk behaviors, PrEP attitudes, and preferences. Researchers will measure the projected uptake of long-acting PrEP, epidemiological impact, and cost-effectiveness over 12 to 18 months. The study includes ongoing monitoring of participant responses to optimize understanding of factors influencing PrEP use.
Actively Recruiting
Researchers are conducting a Phase 23, multisite, randomized, open-label trial to study first-line treatments for non-small cell lung cancer NSCLC. This trial includes two substudies focusing on different NSCLC histological subtypes due to variations in standard chemotherapy choices. The study aims to evaluate the safety, effectiveness, and behavior of the investigational drug pumitamig combined with chemotherapy and compare it to pembrolizumab plus chemotherapy. Participants in each substudy first join a Phase 2 part where they receive one of two doses of pumitamig plus chemotherapy. In the Phase 3 part, they are randomized to receive either pumitamig plus chemotherapy or pembrolizumab plus chemotherapy. Additional participants in China will be enrolled in a Phase 2 arm to further evaluate a selected dose. Independent committees will review safety data and tumor scans throughout the study. Participants will be involved for up to 64 months, undergoing treatments through intravenous infusions. Their health will be monitored regularly to track side effects, tumor response, progression-free survival, overall survival, and quality of life through questionnaires and scans. Safety assessments include monitoring adverse events and treatment tolerance, with follow-up visits extending up to several years to assess long-term outcomes.
Actively Recruiting
Researchers are evaluating Remdesivir VEKLURY4 in children under two years old who are hospitalized with confirmed respiratory syncytial virus RSV infection. This Phase II, open-label, randomized controlled trial aims to assess the safety, antiviral activity, and acceptability of a five-day course of Remdesivir compared to standard care. The study focuses on how well the treatment reduces RSV replication and its safety profile in this young patient group. Participants will be randomly assigned to one of two groups one group will receive standard care alone, which may include oxygen therapy, bronchodilators, intravenous fluids, steroids, antibiotics, and treatment for underlying diseases as needed. The other group will receive Remdesivir by intravenous infusion every 24 hours for five consecutive days in addition to the standard care. Treatment doses will be based on the childs weight at the time of randomization. The study will enroll about 120 children and follow them throughout hospitalization plus a final visit 7 to 10 days after Day 6. Throughout the study, researchers will monitor participants for safety and tolerability of Remdesivir, measure RSV viral load, and assess the treatments effectiveness over one week. Assessments will include clinical observations, laboratory tests, and evaluations of respiratory status. The follow-up after hospitalization will help determine the lasting effects and acceptability of the treatment in this population.